1. [Pathophysiology and therapy of L-Dopa-induced dyskinesia].
- Author
-
Hadj Tahar A, Bézard E, Grondin R, Gross CE, and Bédard PJ
- Subjects
- Animals, Basal Ganglia anatomy & histology, Basal Ganglia physiology, Disease Models, Animal, Dyskinesia, Drug-Induced prevention & control, Humans, Receptors, Adrenergic drug effects, Receptors, Adrenergic physiology, Receptors, Dopamine drug effects, Receptors, Dopamine physiology, Receptors, Glutamate drug effects, Receptors, Glutamate physiology, Receptors, Opioid drug effects, Receptors, Opioid physiology, Receptors, Purinergic P1 drug effects, Receptors, Purinergic P1 physiology, Dopamine Agents adverse effects, Dyskinesia, Drug-Induced drug therapy, Dyskinesia, Drug-Induced physiopathology, Levodopa adverse effects
- Abstract
Involuntary movements, or dyskinesias, represent a debilitating complication of levodopa therapy for Parkinson's disease. Dyskinesia is, ultimately, experienced by the vast majority of the patients. Despite the importance of this problem, little was known about the cause of dyskinesia, a situation that has dramatically evolved in the last few years. The present review presents: 1) the current understanding of dyskinesia pathophysiology and 2) the therapeutic modalities, mainly non-dopaminergic, available or in development. We here show that the questions raised by the dyskinesia may have a clinically-driven pharmacological answer: the symptomatic treatment of dyskinesia, the prevention of the priming and the de-priming of the neural networks.
- Published
- 2003